Silence Therapeutics plcSLNEarnings & Financial Report
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.
SLN Q3 2025 Key Financial Metrics
Revenue
$159.0K
Gross Profit
$95.0K
Operating Profit
$-26.2M
Net Profit
$-21.0M
Gross Margin
59.7%
Operating Margin
-16505.7%
Net Margin
-13181.1%
YoY Growth
-89.4%
EPS
$-0.15
Financial Flow
Silence Therapeutics plc Q3 2025 Financial Summary
Silence Therapeutics plc reported revenue of $159.0K for Q3 2025, with a net profit of $-21.0M (-13181.1% margin). Cost of goods sold was $64.0K, operating expenses totaled $26.3M.
Key Financial Metrics
| Total Revenue | $159.0K |
|---|---|
| Net Profit | $-21.0M |
| Gross Margin | 59.7% |
| Operating Margin | -16505.7% |
| Report Period | Q3 2025 |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $15.7M | $756000 | $1.5M | $142000 | $224000 | $159000 |
| YoY Growth | N/A | N/A | N/A | -99.1% | -70.4% | -89.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Assets | N/A | N/A | N/A | $185.3M | $165.2M | $146.8M |
| Liabilities | N/A | N/A | N/A | $72.6M | $71.1M | $72.7M |
| Equity | $156.8M | $142.5M | $126.7M | $112.7M | $94.2M | $74.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|
| Operating CF | $-9.1M | $-5.4M | $-25.6M | $-12.3M | $-21.8M | $-10.9M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M